Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Changweitong granules is a Traditional Chinese Medicine (TCM) formulation developed by Hainan Tongzhou Pharmaceutical Co., Ltd. for the treatment of gastrointestinal disorders. It is specifically indicated for patterns characterized by heat accumulation and blood stasis in the intestines, a condition often associated with symptoms such as abdominal pain, distension, and constipation. The drug has undergone Phase 1 clinical evaluation in China to assess the safety, tolerability, and pharmacokinetics of single and multiple oral doses in healthy volunteers. As a TCM granule product, it is composed of multiple botanical extracts intended to clear internal heat and resolve blood stasis to restore gastrointestinal function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Changweitong granules.